This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Brown, R. Articles by Mitchell, R. PubMed PubMed Citation Articles by Brown, R. Articles by Mitchell, R.

The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma

Authors' Affiliations: Departments of ¹ Electrical and Computer Engineering, ² Clinical Neurosciences, ³ Oncology, ⁴ Radiology, and ⁵ Pathology and Laboratory Medicine, ⁶ Seaman Family MR Research Centre, ⁷ Clark Smith Brain Tumor Centre of the Southern Alberta Cancer Research Institute, and ⁸ Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta; and ⁹ Department of Neurology, University of Virginia, Charlottesville, Virginia

Requests for reprints: Gregory Cairncross, Foothills Medical Centre, 1403 29th Street Northwest, Calgary, Alberta, Canada T2N 2T9. Phone: 403-944-1260; Fax: 403-270-7878; E-mail: jgcairnx{at}ucalgary.ca.

Background: Some patients with low-grade glioma have extraordinarily long survival times; current, early treatment does not prolong their lives. For this reason, therapies that sometimes have neurologic side effects are often deferred intentionally.

Methods: In a study of oligodendrogliomas, we used a quantitative method of MR analysis based on the S-transform to investigate whether codeletion of chromosomes 1p and 19q, a marker of good prognosis, could be predicted accurately by measuring image texture.

Results: Differences in texture were seen between tumors with codeletion of chromosomes 1p and 19q and those with intact 1p and 19q alleles on contrast-enhanced T1-weighted and T2-weighted MR images. Quantitative MR texture on T2 images predicted codeletion of chromosomes 1p and 19q with high sensitivity and specificity.

Conclusions: This new method of MR image interpretation may have the potential to augment the diagnostic assessment of patients with suspected low-grade glioma.